The first clinical investigations of anti-EGFR therapeutic antibodies were limited to colorectal carcinomas (CRCs) positive for EGFR expression by immunohistochemistry (IHC); subsequent analysis of disease outcomes revealed no relevance of EGFR status in tumor response, however, RAS mutations emerged as a strong predictor of tumor resistance to cetuximab or panitumumab [9,10]. This evidence concerns the gene EGFR and neoplasm.